Neurelis Inc
| File:Neurelis Inc.png | |
| Private | |
| ISIN | 🆔 |
| Industry | Pharmaceutical Biotechnology |
| Founded 📆 | March 10, 2007[1] |
| Founders 👔 | Craig C. Chambliss David F. Hale |
| Headquarters 🏙️ | , , |
Area served 🗺️ | |
Key people | Craig C. Chambliss (President and CEO) David F. Hale (Director) Jenny Alonso (CCO) |
| Members | |
Number of employees | |
| 🌐 Website | neurelis |
| 📇 Address | |
| 📞 telephone | |
Neurelis Inc. is a private specialty pharmaceutical company based in San Diego, California, US, providing treatment options for epilepsy and central nervous system disorders.[2]
History[edit]
Neurelis was founded by Craig Charles Chambliss and David F. Hale in 2007 by investing about US$4 million.[3] Neurelis is focused on the development and commercialization of product candidates for epilepsy and the broader central nervous system (CNS) market. On 10 January 2020, the US Food and Drug Administration (FDA) approved Neurelis' VALTOCO, a diazepam nasal spray.[4]
Acquisition[edit]
Neurelis has acquired Aegis Therapeutics, a drug delivery technology company based in San Diego, in 2018.[5] This acquisition helps Neurelis to include Aeagis’ Intravail which is designed to increase spray absorption with less variability, in their core product Valtoco. Through this purchase, Neurelis gains licensing deals with Dr. Reddy's Laboratories and Opiant Pharmaceuticals.[3]
Products[edit]
The company's core product is called Valtoco, a formulation that incorporates diazepam, an existing drug used to control seizures and alcohol withdrawal, with a vitamin E-based solution that is delivered using a nasal spray when a sudden seizure episode occurs. The product uses an absorption enhancement technology called Intravail, developed by Aegis Therapeutics.[6][7] Valtoco is indicated for the treatment of intermittent, stereotypic episodes of frequent seizure activities (seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in adult and pediatric patients 6 years of age and older.[8]
References[edit]
- ↑ "Neurelis Inc - Bloomberg". Bloomberg.
- ↑ "Nuerelis Inc". LinkedIn.[self-published]
- ↑ 3.0 3.1 Whitlock, Jared (3 December 2018). "Neurelis Buys Aegis Therapeutics". San Diego Business Journal. Archived from the original on 4 December 2018. Retrieved 26 December 2020. Unknown parameter
|url-status=ignored (help) - ↑ "Neurelis Announces Rapid and Broad Payer Coverage of Valtoco". PR Newswire. 8 June 2020. Archived from the original on 31 October 2020. Retrieved 26 December 2020. Unknown parameter
|url-status=ignored (help) - ↑ "Neurelis Announces Acquisition of Leading Drug Delivery Technology Company". Drug Development & Delivery.
- ↑ "When Will There Ever be a Cure for Epilepsy?". Nanalyze. 19 April 2019. Archived from the original on 31 October 2020. Retrieved 26 December 2020. Unknown parameter
|url-status=ignored (help) - ↑ "Neurelis Files New Drug Application With The FDA For VALTOCO™ Nasal Spray". BioSpace. 25 September 2018.
- ↑ Levy, Sandra (10 March 2020). "Neurelis launches Valtoco". Drug Store News. Archived from the original on 5 September 2020. Retrieved 26 December 2020. Unknown parameter
|url-status=ignored (help)
External links[edit]
This article "Neurelis Inc" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Neurelis Inc. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
